Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Kisspeptin-10

KP-10, Metastin (45-54), Kisspeptin-10 (human), KiSS-1

Quick Stats
Studies 877
Trials 47
Score 2
2025 pubmed

Kisspeptin-10 protects against HIV-1 Tat-induced blood-brain barrier dysfunction and neuroinflammation via RhoA/ROCK pathway: Implications for HAND therapy.

Cheng. Chao C; Xiong. Dong D; Zheng. Fengwei F; Wang. Tianze T; Li. Weixin W

Key Findings

  • Kisspeptin‑10 lowered oxidative stress markers (MDA) and restored antioxidant enzymes (CAT, GSH‑Px, T‑AOC) in mouse brain tissue exposed to HIV‑1 Tat.
  • It reduced pro‑inflammatory cytokines (IL‑6, MCP‑1, TNF‑α) triggered by Tat.
  • Kisspeptin‑10 preserved blood‑brain barrier integrity by increasing Claudin‑5 expression and preventing increased permeability in both mice and bEnd.3 endothelial cells.
  • The protective effect depended on inhibition of the RhoA/ROCK signaling pathway; forcing RhoA activation cancelled the benefit.

Practical Outcomes

  • For now, kisspeptin‑10 is a research tool, not a ready‑to‑use supplement. The data suggest it might have neuroprotective, anti‑inflammatory, and antioxidant properties that could be relevant for brain health, but human dosing, safety, and efficacy are unknown. Biohackers should watch for future studies before considering any self‑experimentation.

Summary

The study shows that a short piece of the hormone kisspeptin (kisspeptin‑10) can protect brain blood vessels from damage caused by a HIV protein called Tat. In mice and brain‑cell cultures, kisspeptin‑10 reduced oxidative stress, lowered inflammation, kept the tight junction protein Claudin‑5 high, and blocked a cell‑signaling pathway (RhoA/ROCK) that normally makes the blood‑brain barrier leaky.

Abstract

This study investigated the effects of Kisspeptin-10 (Kp-10) on HIV-1 Tat-induced blood-brain barrier (BBB) permeability and oxidative stress using both in vivo and in vitro models. In vivo, one hour after intraperitoneal administration of 50 nmol/kg (DSS)*6-Kp-10, mice were intravenously injected with HIV-1 Tat (100 μg/kg). Markers of oxidative stress, inflammatory cytokines, and BBB integrity were then evaluated. In vitro, bEnd.3 cells were treated with HIV-1 Tat and Kp-10, and endothelial permeability, Claudin-5 expression, and RhoA/ROCK signaling were assessed. HIV-1 Tat increased oxidative stress in the cortical tissue of mice, as evidenced by elevated malondialdehyde (MDA) and reduced levels of catalase (CAT) activity, glutathione peroxidase (GSH-Px) activity, and total antioxidant capacity (T-AOC). These effects were attenuated by Kp-10 administration. Additionally, Kp-10 suppressed the expression of pro-inflammatory cytokines, including interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor-alpha (TNF-α), in response to HIV-1 Tat. Notably, Kp-10 mitigated HIV-1 Tat-induced BBB dysfunction by upregulating Claudin-5 expression in the cortical tissue of mice. In vitro, bEnd.3 cells were treated with HIV-1 Tat in the presence of Kp-10 at various concentrations. Our results demonstrated that Kp-10 prevented HIV-1 Tat-induced increases in trans-endothelial permeability and reductions in transepithelial electrical resistance (TEER) by upregulating Claudin-5 expression. Furthermore, Kp-10 inhibited the activation of the RhoA/Rho-associated protein kinase (RhoA/ROCK) signaling pathway in bEnd.3 cells. Overexpression of the RhoA-GTP Q63L mutant abolished the protective effects of Kp-10, suggesting that these effects are mediated through the RhoA/ROCK axis. These findings suggest that Kp-10 might be a potential therapeutic agent for HIV-associated neurocognitive disorders (HAND).

Study Information

Provider

pubmed

Year

2025

Date

2025-07-23T00:00:00.000Z

DOI

10.1016/j.neuro.2025.07.008

References

36